BRIEF-Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing

Allogene

Allogene

ALLO

0.00

May 13 (Reuters) - Allogene Therapeutics Inc ALLO.O:

  • ALLOGENE THERAPEUTICS INC - ENTERS TERMINATION AGREEMENT WITH OVERLAND THERAPEUTICS ON MAY 12, 2026 - SEC FILING

  • ALLOGENE THERAPEUTICS INC - TERMINATES EXCLUSIVE LICENSE AGREEMENT WITH OVERLAND THERAPEUTICS EFFECTIVE MAY 12, 2026 - SEC FILING

  • ALLOGENE THERAPEUTICS INC - NO TERMINATION PAYMENTS MADE IN CONNECTION WITH TERMINATION AGREEMENT - SEC FILING

  • ALLOGENE THERAPEUTICS INC - TO HOLD ABOUT 3% OF OVERLAND EQUITY AFTER SURRENDERING PORTION FOR NO CONSIDERATION - SEC FILING

Source text: [ID:n0001628280-26-034583]

Further company coverage: ALLO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.